Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
July 21, 2020
Earnings Call Speaker Segments
Nick Rolli
executiveHello, and thanks for being with us today. Earlier this morning, we put out a press release with full details about how we performed in the second quarter of 2020. That release can be found at www.pmi.com, or through the PMI Investor Relations app. A glossary of terms — covering the definition of reduced-risk products, or RRPs, along with adjustments, other calculations, and reconciliations to the most directly comparable U.S. GAAP measures — plus extra heated tobacco unit market data, appears at the end of the webcast slides for today, which are available on our website. Except where noted otherwise, any mention of IQOS refers to our IQOS heat-not-burn products. Also, keep in mind that our estimates for total industry and market share for this quarter are constrained by limits on how available and accurate industry data is in some geographies while pandemic-related restrictions are in place. Figures shown on a like-for-like basis reflect pro forma 2019 results, adjusted for the deconsolidation of our Canadian subsidiary, Rothmans, Benson & Hedges Inc., which took effect March 22, 2019. Remarks today include forward-looking statements and projections of future results. I point you to the forward-looking and cautionary statements disclosure in today's presentation and press release, where you can review the various factors that might cause actual results to differ materially from projections or forward-looking statements. Please also take note of the additional forward-looking and cautionary statements concerning COVID-19. I'm now happy to hand things over to Emmanuel Babeau, our Chief Financial Officer. Emmanuel?
Emmanuel Babeau
executiveThanks, Nick, and hello everyone. I want to wish safety and good health to each person listening, as well as to those you care about. Looking after the health and well-being of the people who work for us, the families they go home to, and the communities in which we do business remains our number one concern. During the period when restrictions have been active, we have put in place rigorous policies and steps aimed at lowering the risk faced by anyone continuing to work at our sites and offices. For every member of our workforce, including those working from home, providing direction and assistance matters just as much. In some places, where the situation locally and the limits set by authorities allow it, we are now starting a step-by-step, tightly controlled move back into the workplace. What our team members have shown in terms of resilience and character through these challenging times continues to inspire me and the PMI management team deeply, and I'd like to take this opportunity to express our gratitude for everything they've done. Turning to our results, the business delivered a strong showing across the first six months of the year even as the pandemic created conditions unlike anything we've seen before. Most notably, IQOS kept up its outstanding trajectory, reaching an estimated 15.4 million users by the end of Q2. We moved our commercial approach quickly toward digital and remote interactions, and we kept IQOS' rates of both user acquisition and brand retention high. Heated tobacco unit volumes increased 24% in Q2 2020 compared with a year earlier, and RRPs made up almost one quarter of net revenues. On top of that, after a pair of extremely challenging months during the quarter caused by the pandemic, conditions in our combustible business are now getting better. With lockdowns gradually loosening in many nations, industry volumes started to rebound in June and in early July. That upturn was especially powered by the EU, which is our biggest region when measured by net revenue and adjusted operating income. When it comes to the persistent challenges linked to COVID restrictions, two stand out: duty-free hasn't bounced back, and in Indonesia those problems are made worse by how pricing works there. We're still dealing with an unpredictable economy, and everyone is hoping we don't see another major wave of the virus. One thing worth highlighting is that even with the extra costs COVID brought on, our operating margin stayed robust in Q2 as well as the first six months. That's a result of RRPs becoming a bigger share of what we do and getting more profitable. Several things contributed here: manufacturing productivity gains spanning both RRPs and combustible products, SG&A reductions achieved by shifting toward digital, dropping or pushing back some projects deemed less important, and the operating leverage that comes from selling more RRP volume. It's not by accident that the three areas where RRPs are most established are the ones fueling these margin results. On July 7, we hit what is genuinely a landmark moment for IQOS — for our mission and for the growth we expect going forward — when the FDA granted authorization for IQOS as a modified risk tobacco product. No other electronic nicotine product has ever been given an MRTP order before IQOS. Having reviewed the extensive body of scientific evidence we submitted, the agency concluded that an exposure modification order for IQOS would help advance public health in the United States, demonstrating that IQOS is fundamentally distinct from combustible cigarettes and a better choice for adults who would otherwise continue to smoke. The agency decided that allowing this IQOS order would likely improve public health as a whole, taking into account both tobacco users and people who don't currently use such products. One important factor for expanding RRPs going forward is establishing a regulatory approach that treats them differently, one that can nudge adults who would otherwise continue smoking to move instead to better options, in line with the harm reduction idea. Under this clearance, a version of IQOS may be sold together with statements affirming that our scientific research is valid regarding the substantial drop in contact with harmful and potentially harmful chemicals present in cigarette smoke. The way the FDA ruled, plus the thorough post-market controls and monitoring that came afterward, which center on preventing use, shows something important: governments and public health bodies around the world can take an inclusive, science-driven path. That path helps adult smokers who would keep smoking otherwise switch to better choices quickly, while also protecting against unintended consequences. Since investors now pay more attention to environmental, social, and governance matters, I'd like to point to our Integrated Report for 2019, which we published recently. It covers many key ESG subjects and metrics, including how our business transformation is measured. You know, one thing worth highlighting: we've broadened those aspirational targets of ours, and they now take in fresh objectives — specifically around how many people in non-OECD nations use our smoke-free products, plus preventing youth access. You can find that report over on our site, pmi.com. So, moving on to how well we did in the year's first six months — no question, it was a really tough stretch, with disruptions hitting all sorts of areas in how we operate, including our supply chain and route-to-market. I'm happy to report that our company has the resilience and nimbleness to ride this out, so the effect on what we deliver to consumers and trade partners stayed minimal. Even with extraordinary challenges in numerous important markets, our net revenues on a currency-neutral basis—aided by a robust first quarter—ended up nearly level compared with the previous year on a like-for-like basis. Thanks to combustible pricing, efficiencies in manufacturing and SG&A, plus the dual RRP margin benefit from increased weight and better profitability, our adjusted operating income margin climbed more than 200 basis points, producing 8% growth in adjusted diluted EPS, all measured like-for-like excluding currency effects. Now I'll turn to how we performed in the second quarter. Lockdowns restricting movement shaped everyday consumption habits in some markets, among them those of workers earning daily wages in developing nations, and threw retail trade into disarray. Because of that, several markets saw a big drop in industry volume in April and May, and the main effect landed on our combustible business. Duty-free sales came in soft, which is what we had expected. Most of the trade and distributor inventory that had accumulated in March was drawn down early in the quarter, and we had to delay a few pricing calls; beyond that, the prior-year comparison was a difficult one. Despite all of this, our performance came in ahead of what we had projected on June 11, the last time we updated our guidance. Currency-neutral net revenue declined 9.5%, while our assumption had been close to the better end of the minus 8% to minus 12% range. In light of that revenue drop and last year's strong profitability, holding our adjusted operating income margin steady felt like a good outcome; it was helped by higher net revenues and profitability in RRPs along with cost efficiencies. Pricing on combustibles, at 3.3%, added to this as well, showing solid pricing across many markets, partly counterbalanced by Indonesia and a tough comparison to the prior year in Turkey. Reported diluted EPS came in at $1.25, well above the top of the range we had guided to before, and that figure includes a smaller currency hit of $0.06. Adjusted diluted EPS reached $1.29, leaving out the reporting adjustment tied to asset impairment and exit cost, which works out to a 7.5% decline excluding currency versus last year. Three factors chiefly explain why results beat expectations. The first is that industry volume bounced back in June, particularly in the EU region where margins run higher, which lifted our net revenues and margin.
Emmanuel Babeau
executiveMoving on, the number of people taking up IQOS went up significantly during that month. In places such as Russia, usage rates were back at levels last seen prior to the pandemic. Across the whole quarter, the overall number of IQOS adoptions ended up only 35% below what we saw before COVID struck. We also got a boost from a few items that don't fall into our standard reporting. These include shifts in trade inventory throughout June, which happened as we prepared for changes to taxes and regulations in Germany, Russia, and Saudi Arabia; the timing of when certain expenses hit; a smaller tax bill — largely driven by a cut to the corporate income tax rate in Indonesia; and changes in the mix of where our profits come from. Taken together, these < > elements accounted for about $0.10 of the better-than-expected EPS figure. Before I get into our guidance, I want to walk through a few of the factors that will shape how the second half of the year plays out. For our combustible products, we expect the business to improve steadily at its core, while IQOS should keep delivering robust expansion. Operating conditions remain unpredictable because of the pandemic, and restrictions could become stricter in certain local areas. We have not built into our guidance the chance—which is still meaningful—that the virus comes back and nationwide shutdowns are imposed once more. It is likewise uncertain how much economic damage all these restrictions will ultimately cause. Even so, over the past several weeks, pandemic-related limits have appeared fairly stable, and we are gaining a clearer picture in several markets. Conversely, certain regions—Indonesia and Latin America among them—still have limited visibility. There's also been no rebound at all yet in Duty Free, and keep in mind that channel accounted for nearly 4% of our net revenues in 2019. Turning to cigarettes, underlying industry volumes are recovering bit by bit as restrictions loosen, but we expect it will take a while before consumers return to typical consumption occasions. We're not factoring in any major, broad-based shift toward down-trading, since that behavior right now is mostly confined to places where an existing trend was already in place because of wide price gaps. Given the pandemic, it makes sense that pricing could take longer to roll out in some markets. Within RRPs, we're seeing robust performance for both device and HTU sales, which shows IQOS user acquisition came in above what we anticipated, alongside ongoing strength in retaining the brand and converting users. Because of how our commercial model is built, we've shown we can move faster toward digital and remote ways of working, and in markets where shops have opened again, that kind of engagement remains at a high level. Even with the extraordinary challenges 2020 has brought, our expectation is that full year adjusted diluted EPS will rise somewhere between 2% and 5% on a currency-neutral like-for-like basis. That works out to an adjusted diluted EPS range of $4.92 to $5.07, which includes an estimated unfavorable currency impact of $0.31 at prevailing exchange rates. Under this forecast, we assume the total industry will decline 7% to 9%, excluding the U.S. and China, while total PMI shipment volume drops 8% to 10% on a like-for-like basis, driven notably by Duty Free and Indonesia. On net revenue, in like-for-like ex-currency terms, we're assuming low-single digit growth, excluding Duty Free and Indonesia. Those two elements mean total net revenue could decline somewhat. The guidance also captures growth of more than 150 basis points in our ex-currency like-for-like adjusted operating income margin. For the whole year, we anticipate an effective tax rate between 22% and 23%, operating cash flow in 2020 of no less than $9 billion, and capital expenditures of $0.7 billion. Every one of these projections presumes that nationwide lockdowns will not happen again in our main international markets during the rest of the year. Turning specifically to the second half, although underlying trends ought to get better step by step, we anticipate that our growth recovery will lean toward the fourth quarter. This presumes a gradual loosening of restrictions throughout the remaining markets, with correspondingly stronger industry recovery as the year draws to a close, plus the compounding effect of more sequential IQOS user acquisition. Looking ahead to Q3, some one-time gains we saw in the first half are expected to reverse, which would hit EPS by around $0.10 and reduce net revenue by roughly 1%. Our forecast also accounts for persistent pressure in Duty Free and Indonesia, the scheduled rollout of 2020 pricing in certain markets, and how costs will be recognized over time. We expect reported net revenues to improve sequentially in Q3, though they'll still fall short of last year's tough comparison. On adjusted EPS, Q3 2020 should come in roughly flat versus Q2 2020, again due to when certain SG&A expenses land and that one-off item from the first half. Reported net revenue ought to keep improving sequentially in the fourth quarter, even though it will probably remain slightly negative versus 2019. Adjusted EPS growth will additionally come from a larger expected realization of cost efficiency tied to new initiatives. I will now go through our second quarter performance in greater detail. As anticipated, our shipment volumes were soft, owing to the impact of pronounced industry declines on our combustible volume stemming from pandemic-related lockdown measures. Prominent market contributors to that decrease were Indonesia, Mexico and the Philippines, each affected by restrictions, lost income for daily wage workers, and substantial price increases. On the other hand, HTU unit shipments continued to grow strongly, reaching a record 18.7 billion units, with the EU region, Japan, and Russia leading the way. Although total volume for the quarter was weak, the improvement we saw sequentially in June and early July is encouraging. Our June in-market sales volume combined was the highest monthly figure so far this year, up 2.8% compared with June 2019. While that increase includes an estimated 3 billion unit impact from inventory changes, it mainly reflects better industry conditions in many geographies, especially the EU region, which declined 7.3% overall in Q2 but still grew in June. We're also pleased to see HTU volumes getting better each quarter, with growth compared to last year staying positive the whole quarter. That strong performance for IQOS means heated tobacco units made up over 10% of total shipment volume in the first half of this year, compared with about 8% in 2019 and 5% in 2018. Even though that share was a bit lower in Q2 2020 since combustible volume was weaker, we expect it to climb over time, thanks to ongoing positive momentum in our RRPs. Net revenues for RRP reached $3.2 billion in the first half, which works out to almost a quarter of PMI's total net revenue in Q2. During Q2, IQOS devices accounted for about 8% of RRP net revenue. That figure reflects a lower proportion of new users relative to existing ones, which stems from the pandemic's impact, an extended replacement cycle, and geographic mix, given that in some markets we keep selling a considerable volume of the less expensive IQOS 2.4 Plus device. Turning now to market share: our total international share declined 0.1 point to 28% in the second quarter, since a larger share for heated tobacco units—rising 0.9 points to reach 3%—was offset by a reduced share for cigarettes. In Indonesia, along with the impact that Duty Free has on our market mix, our market share took a hit—volumes dropped significantly in that country, and our share there is usually far above the international average.
Emmanuel Babeau
executiveThe loss from customers moving to IQOS was essentially offset by wins elsewhere. In markets where IQOS has established a solid presence, our share increased almost without exception. As a result, we saw a substantial gain in combined market share throughout the EU region, Japan, and Russia. Additionally, in many markets Marlboro is disproportionately represented in social smoking occasions, and those occasions naturally declined during COVID-related lockdowns. We expect Marlboro's share to recover once restrictions are lifted. In Indonesia's cigarette market, headwinds accumulated during the second quarter. A severe impact from pandemic-related limits on daily consumption compounded the effects of tax-driven pricing and retail disruption. Industry volumes fell 22%, not counting trade inventory movement, while our shipments dropped 28%. Three broad dynamics explain our share loss. First, inside the Tier 1 segment, price gaps are still wide, reflecting our price leadership over the past 18 months and the delayed enforcement of the minimum retail price. Along with the COVID effect, that has contributed to the end of performance for our premium-skewed portfolio, even though A Mild showed better sequential performance. Enforcement of the minimum selling price has now begun. Government inspectors are back in the field. That said, full enforcement and the resulting trade flow-through of compliant product might not be finished until the fourth quarter. Second is the robust expansion of the tax-advantaged below Tier 1 segment, which, together with tax-driven pricing and the 2020 pandemic situation, has produced more down-trading. This was designed for small players with production below a certain volume threshold. Yet the segment is not operating within the spirit and intent of the law. With the segments now at approximately 25% of the market, this represents a serious threat to government excise revenue, and the correction of volume-based tax tiers has become urgent. Third, the stricter public mobility restriction in urban areas, where our share is higher, has disproportionately impacted our portfolio. However, our market share sequentially improved in June, supported by strength of our brands. Even though there are indications the market is getting better, conditions are still tough. Our current projection is that the industry as a whole will shrink by about 15% across the entire year, which takes into account steady quarter-over-quarter gains in daily consumption following an especially soft second quarter. In this important market, we remain completely dedicated to turning in a stronger performance. Through the rest of the year, we have several commercial efforts underway aimed at drawing on the equity within our brand portfolio. It covers things like rolling out fresh options within the expanding SKT category and the full-flavor SKM category — for example, Dji Sam Soe 12, which came out in March, and Marlboro Filter Black 16, which arrived this month. That said, now that the minimum retail price is being enforced, the biggest structural problem still left on the table is the tax system that's tiered by volume, since it plainly gives the super-low segment an edge when it comes to growth. If nothing changes, that's going to deal a serious blow to the government's excise revenue during this year. We share the view of the public policy expert and economist who are calling on the government to deliver greater predictability and a level playing field — by overhauling the multi-tier excise tax structure and applying the minimum retail selling price strictly, with no exceptions, throughout Indonesia. On the whole, although near-term difficulties persist, the structural headwinds in the market can be tackled via government action. Those headwinds tied directly to the pandemic are probably temporary, and with our brands being strong, we have a sturdy foundation for rebuilding our share. Turning now to how our RRP is performing: we put the total number of IQOS users at 15.4 million as of June 30, versus an estimated 14.6 million in the previous quarter; that works out to roughly 4 million more adult users than at this point a year ago — a remarkable feat under these conditions. It shows broad momentum in user growth across every key IQOS geography, among them Japan, the EU region, and Russia. We also estimate that out of that total, 72%, or 11.2 million adult smokers, have quit smoking and moved to IQOS, while the rest are at differing stages of conversion. Since the pandemic began, we've noticed an early indicator that smokers are becoming more willing to switch to RRPs, and we'll be monitoring how that trend develops going forward. In addition, we're hopeful that the FDA's decision to grant a modified risk tobacco product order for one version of IQOS will gradually contribute to greater awareness of the heated tobacco category and of why switching to IQOS beats continuing to smoke. As for overall share performance, IQOS HTUs continue to deliver outstanding results. Taking a look at overseas territories where IQOS has already launched, our heated tobacco units were the number-three brand globally for the second quarter, holding 6.3% share. That compares with 4.5% during Q2 2019 across the same set of markets, and it happened despite the fact that nationwide availability is still absent in quite a few places. Within the European Union, we added an all-time high number of IQOS adopters in Q2, hitting 4.3 million — a striking figure considering everything going on with the pandemic. The gains were driven by robust performance in Italy, the Czech Republic, Poland, and Germany, alongside markets that have traditionally been slower, such as the U.K., where heated tobacco unit volumes climbed over five times higher than the equivalent quarter last year, as well as Spain. In both of those latter markets, national offtake share exceeded 1%, even with only modest distribution—sorry, disruption. During the second quarter, HEETS accounted for 3.9% of total industry volume, a figure reduced by roughly 0.2 points owing to a pantry-loading effect among consumers. Adjusted for that, share climbed 0.3 point from the prior quarter, while in-market sales volume came in 5% above Q1 2020. I'd also direct you to the appendix, where we lay out share for key EU markets and global key cities—useful as an indicator of how much national share growth is possible. In Russia, IQOS continued to post a strong result, gaining 3 points to reach 5.9% share. Sequentially, though, versus 2020's first quarter, HEETS share fell 0.6 points, a reflection of a larger combustible market during the quarter, driven by greater daily usage in the warmer months plus trade inventory building ahead of July's launch of track-and-trace. A better gauge is sequential in-market sales, up roughly 12%, against 3% sequential growth in Q1. In Japan, reported share overall for heated tobacco units hit 20% during the second quarter, helped by line extensions across both Marlboro HeatSticks and HEETS. IQOS users climbed to an estimated 5.8 million in total, with an estimated 4.3 million having quit smoking and moved to IQOS. If we consider adjusted total tobacco—counting cigarillos and factoring in trade inventory shifts—the share held by our HTU brands climbed two points compared with the same quarter last year, and 0.7 points versus the prior quarter, landing at 18.5%. Sequentially, adjusted in-market sales volume for those HTU brands grew 4.9% in Q2 2020. That helped drive the heated tobacco category as a whole past 25% of total tobacco share for the second quarter. Alongside strong RRP gains in existing markets, IQOS continues to broaden its geographic reach. Despite restrictions tied to the pandemic, we leveraged our digital tools to launch in four additional markets: Austria, North Macedonia, Montenegro, and Saudi Arabia.
Emmanuel Babeau
executiveWith that, IQOS can now be purchased in 57 markets altogether. What matters is that we still intend to broaden our smoke-free lineup during the latter half of the year, introducing IQOS VEEV within e-vapor and a licensed KT&G offering in chosen markets. To wrap up today's presentation, our prospects for growth continue to be robust. IQOS's ongoing momentum amid the extraordinary conditions created by the COVID pandemic shows the structural growth that characterizes RRPs, and we remain on course to hit our 2021 goal of 90 billion to 100 billion heated tobacco unit shipments. Nearly 25% of our net revenue now comes from RRPs, and we anticipate that share will rise as time goes on. Since digital efficiency, operating leverage driven by scale, and productivity savings are all pushing RRP profitability higher at once, this dynamic is quite favorable for our margin outlook. The landmark modified risk tobacco product authorization for IQOS offers yet more proof of the integrity behind both the product and the brand proposition, and it underscores why governments need to adopt regulation grounded in science. Beyond that, following a tough April and May, the industry has now begun to recover, which gives us clearer visibility for the remainder of the year. It has also become evident that the pandemic's impact on the Duty Free business, along with the particular situation in Indonesia, will last no less than one more quarter. Our forecast of sequential improvement across the second half of 2020 takes these factors into account. We presume the worldwide economic climate will probably weigh on total cigarette volume and trigger some down-trading in particular markets. We have encountered this kind of dynamic previously across many markets, where our business performance has proven resilient. As a reminder, we anticipate that the unprecedented declines seen in Q2 2020 will give way to an easier comparison next year. We are likewise still dedicated to growing our market share via RRP expansion and by preserving our leadership position in combustible. A sustained, intense emphasis on costs backs this up. We continue to be on course to achieve our objective of more than $1 billion in efficiency by 2021, via both manufacturing productivity and SG&A savings. On top of that, we have further opportunities stemming from shifts in how we work after the pandemic, among them an acceleration of digital activities. Crucially, our balance sheet and financial position remain solid, and our dedication to the dividend has not wavered. Finally, once COVID-related headwinds fade, we anticipate resuming growth in line with the currency-neutral compound annual growth rate in our 2019 to 2021 algorithm of no less than 5% net revenue growth and no less than 8% adjusted diluted EPS growth. Thank you. I'm now glad to take your questions.
Chris Growe
analystHello there, and it's great to get an update from you, Emmanuel.
Emmanuel Babeau
executiveMorning to you.
Chris Growe
analystI want to start by saying good morning, and I want to praise the fact that you've provided guidance covering the year. Uncertainty clearly exists, yet we truly value the outlook you've shared despite all the unpredictability present in today's market; so, thanks for doing that. My first question, if I may, concerns IQOS results. It's clear that performance was really robust during the quarter. What I'd like to grasp is the way you handled your IQOS spending. Did you reduce it during Q2? Some outlets had obviously shut down, and did you resume that spending in June, during Q3? I'm just trying to get a sense of the momentum this product line carries as we head into the back half of the year.
Emmanuel Babeau
executiveYes, certainly, Chris. Naturally, IQOS stays our number one priority, and our efforts and investments are concentrated on IQOS. So even amid this difficult climate, we continued putting money behind IQOS. Naturally, we needed to factor in how the environment was evolving, and plenty of investments wound up deferred since they stopped being sensible. It simply wasn't feasible to modify them and carry them out. Several aspects of the commercial model needed revisiting, particularly wherever in-person interaction was involved. New product launches we'd been preparing had to be pushed back; so relative to the original plan there was unmistakably some trimming of investment, yet we remained fully dedicated to boosting investment behind IQOS. In my view, what's encouraging about this Q2 and the H1 overall is that these investments are delivering a rising return, since we're, first, dealing with what I'd call the fixed portion of investment, the structure required to fund our RRPs and IQOS, and our volume is expanding; so we spread that investment across a bigger volume and sales base. That let us bring down the first, fixed cost, so to speak, and lift profitability as a result. There's likewise a variable portion of investment relating to acquiring or retaining consumers, and there, I'd note, throughout the crisis, we're obviously already addressing that. We've definitely been speeding up the use of digital customer experience and methods of engaging them more efficiently and digitally, which will scale better and bring down that variable cost per user, which is likewise great news for IQOS's future and its profitability.
Chris Growe
analystThanks for that, and if possible I'd like to ask just one more thing; regarding pricing, it came in somewhat better than I'd anticipated during the quarter, which was excellent. I'm simply wondering, you mentioned possibly postponing certain pricing choices. Is it merely a postponement? Or have you stepped back from pricing decisions given that you've observed some down-trading in certain markets? I'm just wondering about how you — what's your approach to the pricing situation there?
Emmanuel Babeau
executiveYes. Well, naturally, when it comes to raising prices, the environment must be factored in; obviously, in markets experiencing severe disruption, where trade is disrupted, where some locations are seeing very difficult developments because of the lockdown, plans for price increases must be reconsidered. So, obviously we factor that in; the potential for price increases that we firmly maintain and that we will keep implementing once COVID has passed is unchanged; but clearly, in this environment, we're finding that what we were planning under normal conditions is, I'd say, neither desirable nor achievable right now, and that might involve some postponement, and I believe we're signaling that for Q3, when there were a number of price increases last year; and this year, I think it may lean more toward Q4, when hopefully things are returning to normal.
Chris Growe
analystAll right, I really appreciate you taking the time.
Emmanuel Babeau
executiveThanks.
Gaurav Jain
analystGood afternoon, and thank you very much. Three things I'd like to ask. First, regarding the EU, you mention a June pickup, especially for IQOS, and we're aware a menthol cigarette prohibition took effect in May. So did IQOS gain anything from that, given that flavors remain on offer there, and you're specifically calling out Poland, a major menthol market? That's what I was wondering about.
Emmanuel Babeau
executiveYes, I appreciate that question. You're completely correct. Everybody knows the menthol prohibition started on May 20. What that really means is that it carried through June. Saying we've gained from it would be premature, in my view. As you're aware, our exposure to that category is limited. So for us, that's likely a favorable development when it comes to how the market moves. I wouldn't claim IQOS's performance is clearly driven by it. It's possible it helped somewhat — I can't rule that out — yet I'd say IQOS performed strongly across the quarter in the EU; again, this highlights how solid IQOS is in the EU during Q2. And my expectation is that Q3 will likely give us a clearer picture regarding the menthol prohibition's effect, potentially on IQOS and on how it touches the remaining CC category.
Gaurav Jain
analystAlright. My follow-up concerns the guidance you've given, which rests on the premise that no additional nationwide lockdowns will occur for the rest of 2020. I understand you're staying away from any 2021 commentary, yet were we to suppose the same holds true next year, then Q2 '20 sets up an extremely easy comparison, since nationwide lockdowns happened in Q2 '20 and in all likelihood won't recur. So might there be a year in 2021 in which your volumes come in roughly flat?
Emmanuel Babeau
executiveIf you'll permit me, I won't get into discussing 2021 right now; that's something we'll address at the appropriate time. What I can do is join you in simply examining the reality that our Q2 is indeed depressed. Our Duty Free market has taken a very heavy hit from the COVID-19 crisis, and should conditions return to normal next year, that would broadly translate into a favorable basis of comparison. For the moment, though, I'll stick to this straightforward, fact-based possibility, should such a scenario indeed be confirmed, and at the appropriate time we will of course share with you what that might imply for our '21 outlook, but it's premature to say anything now.
Gaurav Jain
analystAlright, thanks. For my final question, I'd like to dig into the travel retail segment a little more. Could you explain in greater detail what that business actually consists of? Travel retail isn't a significant channel in the U.S., as we're aware, and you have no presence in China. So it appears a large portion of it likely sits within EU travel. Should we then be watching travel trends inside the EU as the way to predict how your travel retail operation will perform?
Emmanuel Babeau
executiveEU is definitely a key market, yes, though I'd say our reach is worldwide. You're correct that we aren't in the U.S. and we aren't in China, yet that doesn't prevent us from gaining when American and Chinese consumers fly into other airports. So the EU region matters, I'd say, but our footprint stretches far wider than that, which means you can't reduce it to European exposure, if you will.
Gaurav Jain
analystUnderstood, though what I wanted to know is whether something like half of your operations involve travel within the EU, or maybe 30% or 40% — can you put any kind of figure on that?
Emmanuel Babeau
executiveNo. Look, I don't believe we disclose such a breakdown, but what I can say is that if I had to put a label on it, it would come to 12%.
Gaurav Jain
analystOkay, brilliant. Thanks a lot.
Emmanuel Babeau
executiveThank you.
Bonnie Herzog
analystThanks. Hi there. I'd like to revisit the topic of bringing in new users, and I'm hoping you can tell us how things are going on the digital side — specifically regarding those virtual guided trials you brought up — and really, what effect is that having on how consumers engage? Also, I'd love to know what share of your new users currently arrive via digital channels.
Emmanuel Babeau
executiveBonnie, thanks for asking. Naturally, we'll reveal whatever we're able to reveal, and that's partly due to confidentiality, since this forms part of what makes us successful, and as we collect the data, it's clear we've been stepping up how we connect with our customers digitally. The original approach, as you're aware, centered first — though not exclusively — on face-to-face interaction via stores, via coaches, and on getting smokers engaged by describing why making the switch to IQOS pays off. Honestly, this began before we ever encountered the COVID crisis. Still, when faced with markets under lockdown and individuals stuck at home, we needed to speed up our digital engagement strategy and build out every tool across all digital touchpoints, and since people were, naturally, at home spending lots of time online, we worked to create complete interaction and full ability to reach out first, to explain, to follow up and, naturally, to deliver a completely remote experience for our consumer. So I can't provide that figure, and I doubt we'd want to disclose it, given how sensitive it is, but what I can say is that we're seeing the proportion of IQOS customers who are fully managed through digital, and that proportion is rising extremely quickly and growing quite substantial. Naturally, the wonderful thing about this is that it scales with ease at a lower cost, something that was likely harder when everything depended entirely on human interaction. Once more, I believe H1 2020 will stand as a milestone for our IQOS business for several reasons: the MRTP decision being one; the gain in profitability within the RRP business being another; and, without a doubt, the speeding up of our digital approach to acquiring and retaining IQOS customers being yet another.
Bonnie Herzog
analystThat's genuinely useful context. And merely considering how much this seems to have sped up your work — and possibly your learning — strikes me as fairly impressive. So when I consider what you managed to accomplish during the quarter and in this climate regarding bringing in more new users than you'd initially anticipated, does that imply your quarterly rate of new user additions, roughly 1 million every quarter across the past several quarters, might rise once the world begins reopening? Put differently, did you discover anything new about strategy that could speed up conversion?
Emmanuel Babeau
executiveWell, I wouldn't go so far as to claim we've reached the point of presenting a vision that will accelerate matters. Still, it certainly confirms that our ambition is entirely legitimate. We're reaffirming the 90 billion to 100 billion stick for next year, and that will result from continued very strong acquisition of new IQOS users. There's no question this digital play will help us reach that target, and as I mentioned, it will do so at a lower cost, which is unquestionably welcome news.
Bonnie Herzog
analystThat's excellent. One last thing from my side, if that's alright. I'd like to ask about the MRTP you got, and hear your thoughts on what comes next — specifically whether there's an opportunity to reach the following tier of reduced-risk approval. I just wanted to get your read on that, and possibly the timing too. Also, I'd like a clearer picture of how you may leverage what the FDA gave you when it comes to changing or adjusting your marketing strategy down the road. How do you plan to work that in? Thank you.
Emmanuel Babeau
executiveThank you, Bonnie. As everyone here can picture, this MRTP authorization is tremendous news — for the company and for consumers alike, I'd say, since I believe it arrives as a real game changer; as you know, I've called it a landmark. Naturally, it begins by confirming all the scientific evidence we assembled, and it will serve as a significant component in — and I think this captures the essence of your question — how do you make use of this MRTP. Perhaps I'll begin with what you asked about the following tier: naturally, the FDA has kept the door open for us to keep talking with them about exactly that next tier. We plan to do so over the next few months. And I'd say the real question is whether a reduced-risk marketing authorization can arrive via a modified claim, via supplying an extra study, or perhaps through some mix of the two. That's what we plan to talk over with the FDA over the next few months and, naturally, we're eager to hold that conversation with them. Now, on what this means on a global scale. Well, first of all — and this matters quite a bit — we're hoping it kicks off the discussion about whether IQOS and heat-not-burn technology constitute a superior product compared with combustible cigarettes. I think that's a hugely, hugely important confirmation. And it truly ought to shift attention to how we deliver this better alternative for the smoker as quickly as we can, I'd say, and across the widest possible geographies — that's genuinely what it means. So we believe that since the FDA is viewed as an extremely respected regulator, since they're approaching this the right way from my perspective — handling both the review of reduced-harm claims on a tobacco product and, simultaneously, the ongoing restrictions on tobacco use — we think this is the correct approach that we'll be able to, I'd say, share with other regulators, and we're hopeful that, naturally, people will examine this decision and will reach their own conclusions from it. To be clear, we already have this kind of decision from a number of regulators around the world; so we think it will simply amplify that. And we're beyond the U.S., where we now hold the authorization to market as a reduced exposure. We're already talking with another nation about lowering the exposure linked to our IQOS product. So I think that's heading in the right direction toward truly setting what the proper priorities ought to be, and with luck, it will speed things up on a global scale.
Bonnie Herzog
analystThank you very much.
Emmanuel Babeau
executiveThank you.
Robert Rampton
analystHi, I have three questions for you. Let's start with Indonesia — could you clarify what we ought to expect for that market when it comes to revenue? Assuming price enforcement happens, would revenue get back to where it stood in 2019, though on a smaller volume base, or will that market only produce 20%? Has the revenue coming from that market been written down by 20% to reflect the lower price tier ratio given these results < >? Thanks.
Emmanuel Babeau
executiveHello, Robert. If I've got your question right, you want to know how we should view Indonesia once the COVID crisis is over and what we ought to take away from it. Let me be clear: there are actually two aspects we need to walk through regarding the situation in Indonesia. The first, naturally, is all the stuff tied to the COVID crisis. To begin with, keep in mind that we entered the year prior to the COVID crisis pointing out that Indonesia was going to be tough in 2020. There was what I'd call a twofold excise duty hike early in the year. For some time now, we've held the lead on price positioning in Indonesia, and we didn't raise prices at the close of 2019. That's what's generating the difficulty, and we said this difficulty would persist until the minimum retail selling price gets put in place. Then COVID hit, and clearly it caused a complete upheaval of the market. We've witnessed the same thing seen in other new economies, with the effect on consumption coming from daily wage workers cutting back how much they consume on an average day. Is it 20%, 30%? Hard to pin down. But it did have an impact, and as we pointed out, it was likely stronger in cities than in rural areas. We've observed some down-trading since there was pressure on purchasing power, and in certain regions of the market there's also been a shift toward a particular category where our presence is smaller, again consistent with down-trading. Beyond that, there was this second-tier system for excise duty tied to — or meant for — low volume, or supposedly low volume, companies that get a far lower excise duty and can create a price gap of 40% to 50% compared with the Tier 1 system. So it's quite significant. We're discussing a market where a cigarette under this second tier system can be sold at a notably cheaper price. And naturally, when down-trading occurs, consumers have sought out cheaper options, and this market was expected to remain at a very low level since it was meant to be given only to very small production volumes. There's been some misuse in how this has been executed, and during Q2, this second tier segment got to 25% of the market, which, as you can picture, on something that was premised on lower volume was not the goal at all, and that has caused even more disruption in the market. So given all these headwinds we've been dealing with, what should we expect? Well, to begin with, on the minimum retail selling price rollout, it has now begun. Implementation will run through Q3, but we don't anticipate much of an effect in Q3, so the advantage from it should show up in Q4. That's the first piece that will make things better. Next, we're obviously working hard to ensure we grow our brands and introduce offers in the most vibrant portion of the market, and I've mentioned Dji Sam Soe and Marlboro, where we're rolling out extensions in that dynamic part of the market; we expect overall that as the COVID crisis fades and we know economists anticipate a robust rebound of the Indonesian economy next year, so we expect overall too that the down-trading pressure will ease as the economy gets better; daily consumption should also get better, so that ought to aid the trend. And the final piece, which naturally we don't control, is this second tier segment, where we'll need reform and we believe it will occur because if not, it's going to hugely cut the country's income, but there's a need for reform to curb the advantage or alter the excise duty structure based on the values category. Well, ultimately to establish a level playing field and for every player to be competing on a fairly equal basis, and we're definitely hoping that it will take effect — will come about as quickly as possible. If all that I've just been describing occurs, well, there's no reason we can't rebound in Indonesia and return to the market share we saw in prior years. Our brands are very strong. We have an amazing commercial operation in the country, and all of that is, naturally, the strengths we'll use to build our rebound in the quarters ahead.
Robert Rampton
analystExcellent, thanks. I really appreciate it.
Emmanuel Babeau
executiveThanks.
Robert Rampton
analystApologies — moving on to my following question, which concerns trading down. I realize you mentioned Indonesia and said you don't anticipate further down-trading ahead, yet could you point out additional markets where down-trading has already appeared? Is it mainly emerging markets?
Emmanuel Babeau
executiveRight. What we highlighted is that trading down might have sped up in a handful of nations where it was likely already apparent prior to the onset of the crisis, so we mention Turkey, we might mention Mexico. Typically these come alongside Indonesia. In those markets, I would say we've witnessed heightened strain on buying power that has set off down-trading. As for what lies ahead, naturally, no one can predict the effect of the economic crisis that everyone is projecting. We have faced this kind of thing previously, so it won't be our first experience steering through an extremely difficult climate, and we've demonstrated historically that we possess a complete ability to steer through such a climate, using the agility, using the headroom and using the levers needed to steer through such a climate. So we shall observe and we will adjust to the circumstances.
Robert Rampton
analystAlright, I appreciate it. That's all I had.
Emmanuel Babeau
executiveThanks.
Michael Lavery
analystThanks. Morning. Could you give an update regarding the HEETS rollout in Japan? Also, you mentioned what I believe was a bit of mix pressure that certainly would have resulted from that, and we did observe share gains, but perhaps provide some insight into how it is performing versus your expectations and what kind of margin effect that has on your operations there?
Emmanuel Babeau
executiveAbsolutely, Michael. So Japan is likely at the leading edge of what you can anticipate in numerous countries as it becomes more mature, I would say, regarding the expansion of heat-not-burn and IQOS. I believe it is logical to offer customers multiple options. And in Japan, I think my initial point will probably concern the fact that the market performed strongly. Obviously, during H1 and in Q2, our shipments and end-market sales in Japan for heat-not-burn worldwide have been increasing at a double-digit rate in Q2. Thus, as you can tell, it is a market that keeps expanding quite well, and HEETS has certainly contributed to that. Therefore, the fact that we operate with both Marlboro and HEETS allows us to truly seize the greatest opportunity in the market. And we observe a highly favorable trend for HEETS, which has taken close to 4% of the market. So you can see it is already a substantial portion of our RRP business in Japan, and that promises very well for what we can achieve with two brands in that country.
Michael Lavery
analystAll right, that's helpful. And one more thing — could you clear something up for me about Indonesia? You mentioned that, based on what you're currently assuming, minimum price enforcement probably won't kick in before September. So when it comes to 4Q, what are you really assuming? Does the guidance reflect a scenario where nothing gets enforced for the whole year, or does it have something baked in that assumes an improvement?
Emmanuel Babeau
executiveNo. Basically, what the guidance assumes is that we capture a significant portion of the benefit during Q4. In other words, Q3 brings us nothing, but we believe that a substantial share of the upside from minimum retail selling price will materialize in Q4.
Michael Lavery
analystAll right, excellent; and here's my final question. Regarding Mexico, where heated tobacco devices have been prohibited from being imported by the government, could you provide some perspective? Your IQOS launch there had only recently begun, so it seems like this may be striking before it gains momentum, but how are you handling that and what does it look like?
Emmanuel Babeau
executiveYes; so — you are completely correct Michael. Fortunately, we had accumulated an appropriate amount of inventory prior to when this ban took effect. Consequently, we are not dealing with a stockout; naturally, we wish this won't persist for an excessive period, since we aren't claiming to possess devices or inventory that will last multiple years, but at present, it isn't a problem. Our hope is that Mexico will examine the FDA's ruling and that this will sway their choice regarding < >. However, it's — as you're aware, it isn't aimed at IQOS. So regrettably, in this instance we are simply the < > of a wider determination, so to speak. With luck, they will reverse that quickly and that will enable us to restart shipping devices into Mexico.
Michael Lavery
analystOkay, great. Thank you very much.
Emmanuel Babeau
executiveThank you.
Adam Spielman
analystHello, many thanks. There are three things I want to ask. The first relates to EPS guidance. Back in June, you predicted — apologies — during June, you projected earnings per share under $1.10, and that proved inaccurate by roughly $0.20 for the quarter closing in June. Now you're offering guidance spanning $0.15. So I'm curious why you consider that span suitable, given that you couldn't even get a forecast right one month out. That's my initial question — it concerns the range, specifically the reason...
Emmanuel Babeau
executiveRight. I hear you, Adam, and thanks for asking. Let's deal with what the figures actually show — it isn't $0.20, since roughly half of that $0.20 you mentioned, by our reckoning, stems from a one-time item that will be offset during Q3. So we didn't exactly stumble at the finish; rather, something we couldn't foresee in early June occurred late in June, which aided how Q2 concluded. Still, you're correct that somewhere around $0.08 to $0.09 was delivered beyond what we'd expected in early June, and I'd say that's — the June period mattered greatly, because essentially we all came to see that lockdowns and confinement persisted through early June, at which point restrictions eased step by step across numerous, numerous regions. Even with plenty of disruption remaining — for example, many individuals still not physically returning to workplaces — we can't say when everything will return to normal. So let's take it that June likely offered fairly solid visibility regarding what lay ahead over the next months. It's precisely from that foundation that we've arrived at this ability to present this outlook and guidance covering the entire year. So once more, June mattered, what we learned in June mattered, and the shortfall wasn't $0.20 but closer to $0.10. Naturally, the opening weeks of July, as we've mentioned, are reinforcing this sort of grasp of the conditions we currently face.
Adam Spielman
analystAll right, that's okay. So what you're implying there is that no sudden $0.10 swing will crop up by the time December wraps up. That strikes me as a notable point. Does it also mean that if things appear to be heading $0.10 higher, you'd find some way to rein it in? Or could we still see roughly a $0.10 move at the close of December, the way we did when June ended?
Emmanuel Babeau
executiveRight, and naturally, as you're aware, my crystal ball is in pieces, so I can't predict whether something like that might occur. My sense is we're offering a thoughtfully built range for where we land, backed by multiple scenarios, and I believe it captures a variety of outcomes, both favorable and unfavorable, which is inevitable whenever guidance gets put together, and we feel this is where things stand right now. Given everything we know, it's the correct guidance and the correct picture for the landing, and I can't comment further. Should developments arise that our scenarios didn't foresee — which is always possible, naturally, and recent months serve as a reminder that not everything can be predicted — then we'll find out. Still, as of now, again with everything we know, based on what we saw from June through mid-July, we believe this guidance is the right one for year-end.
Adam Spielman
analystAll right, thanks a lot for that. And this is a question that's genuinely harder to pose than to answer, in a way. May I shift to a totally separate topic — margin expansion, particularly within the RRP portfolio. So you mentioned that during this quarter you felt quite encouraged, in part since RRPs now make up a bigger share of the overall business, but also because inside that, RRP margins have risen, partly as a result of the shift — the move you made toward digital; and I suppose what I want to ask is, when it comes to RRPs, what's the right way to think about margins? Clearly there's a whole mix dimension, but that isn't really what I'm asking. What I'm asking is whether you believe you've now reached a solid level, and yes, it will keep growing from here, though maybe at a more modest pace than in Q2, or whether you believe that quarter after quarter we could keep seeing truly striking improvements in RRP margins, say, over roughly the coming 2 or 3 years? This is somewhat of a long-term question, not a 2020 question.
Emmanuel Babeau
executiveNo, it is, Adam, and it's a completely legitimate question. Let me begin by recalling what the IQOS and RRPs model looks like. It begins with the consumable, which, as you're aware, today commands a higher value on a per-stick basis, all right, and that is entirely inherent to this RRP business, and it's also a business where, compared with CC, we're simultaneously enhancing our production methods and boosting productivity, and so, if you examine the gross margin on the HTUs, there is a certain positive — so we begin, naturally, from this advantageous position I just outlined, and there exists a possibility of, let's say, a favorable trajectory; after that come the devices, all right, which as we've observed represent a modest share of the total, yet a significant one; and regarding these, I believe we've been explicit that margins can vary depending on the type of device, but we're willing to sometimes earn nothing or under certain circumstances even take a loss, since ultimately that forms part of the investment we undertake to bring in new customers. So that's where we start; and beneath that, naturally, you have the existing machinery we must build out to turn smokers into IQOS users and then keep them; and with that machinery too, we will make improvements as we expand the top line on RRPs. Efficiency is improving — we lean more on digital, as we've mentioned — and I'd describe it as fine-tuning the machine while simultaneously boosting the engine's power and, I'd add, bringing down what that engine costs. So that will carry on contributing favorably. I'm not sure if "impressive" is the right word, and I don't know what you'd attach to it, but you definitely ought to anticipate that we'll steadily expand the margin on RRPs in a significant way as IQOS and RRPs keep growing. That is unquestionably what we're aiming for.
Adam Spielman
analystAll right. Let me attempt to get a bit more exact regarding what "impressive" means here. You obviously aren't going to give me the precise margin figure, yet it's equally plain that margin expanded extremely sharply during '20 — across the opening six months of 2020 compared with the prior year. So I guess what I'm really asking is whether we ought to anticipate a comparable lift once more in 2021, looking only at the RRP business, or will it turn out to be far smaller than what 2020 delivered?
Emmanuel Babeau
executiveAdam, I'm not going to address whether it lands higher or lower. What I can say is this: we think there's considerable room remaining for us to continue enhancing margin, though I'll refrain from saying anything beyond that.
Adam Spielman
analystAll right, that works. Thanks a lot.
Emmanuel Babeau
executiveAll right, thanks.
Vivien Azer
analystHello, and good morning. Thanks very much. I'd like to start with a question about Marlboro. You mentioned that you'd already observed some modest down-trading in certain markets, such as Turkey and Mexico, and I appreciate that commentary. Those are strong Marlboro markets, so I'm trying to reconcile that remark with your claim that Marlboro's market share will bounce back because of its unusually large exposure to social occasions. So I'm curious: how much of the margin pressure — sorry, how much of the market share pressure — do you believe stems from down-trading in specific markets with a heavy Marlboro presence, as opposed to the social occasions factor? Thank you.
Emmanuel Babeau
executiveWell, I believe you're correct that two factors are at work behind Marlboro, and Q2 proved a tough quarter for the brand. It lost some share partly because of down-trading, as you noted, and there are a handful of markets where that's visible, but I'd also say that to a significant degree, in many markets where Marlboro holds a large share, it's due to social activity that essentially vanished throughout Q2. Meanwhile, incidentally, you have markets like the Philippines, where Marlboro has actually been expanding at a healthy pace. So it's a mixed picture, I'd say — not a single direction, and somewhat more complicated than that. Still, we're definitely confident Marlboro can recover strongly, first through everything tied to social consumption, and we should certainly see some recovery even in countries where down-trading occurred during this period, once the COVID crisis hopefully subsides. As for the down-trading, is it truly Marlboro moving downward, or more mid to low? I think even the real impact — and I mentioned the Philippines, a market where the situation has been tough, and even so we saw a good trajectory for Marlboro. I believe Marlboro gained 3 points of market share in the quarter, so that's pretty solid. So I'd say, when we discuss down-trading, I'm not certain it's been the primary impact on Marlboro; rather, down-trading is more mid-pricing shifting to lower pricing, and the largest impact on Marlboro that we observe is this lack of social moments where Marlboro is a key brand. So we hope that will allow a strong and swift recovery for the brand.
Vivien Azer
analystThat helps, thanks. Now for my follow-up, regarding how IQOS is developing — when I take a quick look at your user figures and set them beside your shipment volumes, it appears there might be some slight erosion when it comes to the typical volume consumed per user. Could that simply be a result of additional markets launching, meaning buyers need time to build up their usage? Or does it reflect a deeper, structural difference in per-person consumption within new areas for combustible cigarettes, one that would carry over to HeatSticks when compared with the IQOS markets that already exist? Thanks.
Emmanuel Babeau
executiveVivien, I can't say we possess anything that would unambiguously indicate that. It's clear that during Q2 the worldwide tobacco sector faced considerable upheaval, which may have played a role in shaping how much people smoked each day, and in a handful of markets this could affect IQOS as well. Yet honestly, nothing in what we hold for Q2 offers evidence or points in that direction.
Vivien Azer
analystUnderstood. Thank you very much.
Emmanuel Babeau
executiveThank you.
Pamela Kaufman
analystI'd like to understand your perspective on the pluses and minuses coming from the excise tax landscape right now. Several things happened over the quarter, such as the VAT hike in Saudi Arabia and the VAT cut in Germany. So what effect do these tax shifts have? And are those costs being handed down to buyers? Also, thinking ahead, how do you see excise taxes shaping up given the economic climate, and what was the pattern you observed after earlier economic slumps?
Emmanuel Babeau
executiveYes, thanks for asking; generally speaking, yes, any change in these taxes, be it excise duty or VAT, gets passed along by us — that's the standard approach; however, perhaps the bigger point is what lies ahead over the next few quarters regarding how the tax landscape will evolve. Well, it's accurate, and that's surely what's driving your question, that numerous nations will confront larger shortfalls — budget deficits stemming from the crisis — and the lure may exist to seek out methods to fund it. To begin with, choices like this are typically taken during the year's fourth quarter. So likely near the close of Q3, or the start of Q4. So we'll have clearer information then. Still, my sense is that compared with perhaps what took place during 2008 to 2009, the situation here looks rather distinct, and plenty of governments are instead attempting to avoid suppressing consumption, and as you're aware, when prices go up, ultimately you can't be certain about the net effect on the — on the revenue you'll end up collecting. And so, it's still unclear what will be decided regarding tax hikes of any kind. I believe it's uncertain. Well, were that to happen, as I mentioned, we witnessed that previously in 2008/2009 as — once more, there's likely a different approach to the crisis, we saw plenty of excise duty hikes across numerous countries, and I believe we've demonstrated our ability to, naturally, endure that sort of situation, and, I'd say, get past that sort of obstacle, and we're certain that were it to occur, we'd manage it once more. However, and I'll repeat my however, things might turn out very differently now, and that's at minimum what we're picking up from various politicians and governments.
Pamela Kaufman
analystThanks. Next, I'd like to hear if you can give us additional detail about the patterns observed as we came out of Q2. You pointed out a specific rebound in Europe. Could you also tell us what you're seeing in other parts of the world? And, stepping back a bit, how do you view the volume picture across markets within your 7% to 9% industry volume projection for the current year? What separates emerging from developed markets, and what's driving that outlook?
Emmanuel Babeau
executiveAbsolutely. Let me return to what we've communicated regarding our Q3 expectations. As we mentioned during June and the opening weeks of July, the market is showing a form of steady, gradual betterment, and worldwide lockdowns have ended. This doesn't mean things have gone back to how they were, yet as I noted, the market appears to be functioning in a somewhat more stable way, with somewhat fewer interruptions. That's a pattern we called out in June, and it explains why we anticipate Q3 net revenue improving sequentially compared with Q2. That is precisely the basis for our view on the remainder of the year; it doesn't imply we'll return to year-on-year growth, and naturally, on top of that, there's a negative effect from H1 that will weigh on the top line, which we pegged at roughly 1% in Q3, yet in Q3 we'll keep witnessing a negative year-on-year movement since numerous markets stay severely disrupted, and naturally, I've mentioned Duty Free and Indonesia, but plenty of other markets will be disrupted owing to the COVID crisis, owing to restrictions, owing to possible economic consequences. All of this will come into play and affect us. I won't go into a market-by-market path, though certainly we'd anticipate mature economies — which is likely what we observed toward the close of the quarter — to demonstrate solid resilience in these conditions and perhaps fewer disruptions relative to a new economy. That would roughly match our sense; and afterward, moving into Q4, as we stated, we still anticipate net revenue improving in Q4 compared with Q2 — Q3, so sequentially, we'll continue to enhance the net revenue figure, yet Q4 might remain negative year-on-year. Thus, we truly must distinguish the quarter-on-quarter movement, the sequential movement, from the year-on-year comparison.
Pamela Kaufman
analystThanks. For my final question: Russia has mattered a lot when it comes to IQOS expansion. Could you share your expectations regarding the economic climate there and how that might affect IQOS uptake in Russia? Also, how did your super premium HeatSticks launch perform? Thanks.
Emmanuel Babeau
executiveIQOS has performed strongly in Russia during Q2 given these conditions; naturally, I won't claim the disruption and some lockdown measures in Russia had zero effect, yet our share for IQOS keeps rising and we're happy with how our RRP is developing in that market. On the whole, the Russian market was likely affected, though only slightly, by what happened. Regarding volume, it declined, and there wasn't a sharp step-up in the underlying volume decrease we observed in Q2. So this is a market that held up rather well throughout the COVID crisis, and once more, we're quite satisfied with IQOS's progress. I won't go into detail about what the trend will look like over the next two quarters. Our expectation is that IQOS market share will continue climbing and that we'll keep delivering solid results on IQOS. The positive part is that we simultaneously held onto our market share in CC; so that was a good accomplishment.
Pamela Kaufman
analystThank you.
Emmanuel Babeau
executiveThank you.
Owen Bennett
analystAfternoon, everyone — trust you're doing fine. I'll be brief. I wanted to revisit the month-over-month gain in industry volumes across the EU during June. Could you split that figure between cigarettes and IQOS, and tell me what primarily drove it? Thanks.
Emmanuel Babeau
executiveYes, that's right — in June, as lockdowns lifted across numerous countries, the trend got better. IQOS, as we mentioned, performed strongly throughout the quarter. Naturally, June brought some pickup, yet the entire quarter was solid for IQOS, and obviously, our CC business — which lockdowns hit hard in certain geographies — showed some acceleration too, and June brought some improvement there. Not every market behaves the same, and in particular, places hurt by reduced tourism suffered more, and I'm referring to Southern Europe. Naturally, those markets usually draw plenty of purchases from visitors abroad plus considerable cross-border traffic, and with borders shut, that vanished. Overall, they performed better as the quarter went on; so that's the sort of pattern we've observed across Europe.
Owen Bennett
analystOkay, very helpful. Thanks very much.
Emmanuel Babeau
executiveThank you.
Nick Rolli
executiveWe appreciate you being with us; this brings the call to an end. Should anything further come to mind, feel free to reach out to the Investor Relations team. Thanks once more. Take care, enjoy the rest of your day, and thank you.
Emmanuel Babeau
executiveThank you all. Talk to you soon. Thanks. Bye.
Operator
operatorThank you as well, everyone, and that brings today's conference call to a close. You're welcome to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.